Anaphylaxis in children and adolescents: The European Anaphylaxis Registry.

Background: Anaphylaxis in children and adolescents is a potentially life-threatening condition. Its heterogeneous clinical presentation and sudden occurrence in virtually any setting without warning have impeded a comprehensive description.

Objective: We sought to characterize severe allergic reactions in terms of elicitors, symptoms, emergency treatment, and long-term management in European children and adolescents.

First European data from the network of severe allergic reactions (NORA).

Background: Occurrence, elicitors and treatment of severe allergic reactions are recognized and reported differently between countries. We aimed to collect standardized data throughout Europe on anaphylaxis referred for diagnosis and counselling.

Methods: Tertiary allergy, dermatology and paediatric units in 10 European countries took part in this pilot phase of the first European Anaphylaxis Registry, from June 2011 to March 2014.

[Contribution of epidemiology to the prevention of drug allergies].

Drug allergies are heterogeneous and multifactorial. They can be life-threatening and lead to market withdrawal of particularly risky drugs. Immunological research has improved our understanding of drug allergies but has not yet been able to prevent them.

[Anaphylactic shock due to recombinant human insulin: follow-up of a desensitization protocol by basophil activation test].

Introduction: Despite the occurrence of a severe allergic reaction including an anaphylactic shock, a drug may remain essential and impossible to replace. This may be the case of insulin in a diabetic patient. We describe the case of an anaphylactic shock to human insulin in whom a desensitization protocol was successfully achieved.